GlassScriptPhysician profile
Debra B Taylor
NPI 1326165218
$1,265.34
in general payments reported to CMS, 2019-2025
12 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $384 · 2023: $106 · 2024: $365 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $347.88 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $326.89 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $288.86 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $106.02 | 2021-2025 | Evenity, Prolia, Repatha |
| Sanofi-Aventis U.S. LLC | $64.00 | 2022-2024 | |
| Medtronic, INC. | $28.30 | 2024 | Intellis Adaptivestim, Minimed 780g |
| Sequel Med Tech, LLC | $20.45 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $20.22 | 2025 | Recorlev |
| Insulet Corporation | $18.15 | 2023 | Omnipod |
| Grt US Holding, INC. | $15.96 | 2022 | |
| Lilly USA, LLC | $15.81 | 2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.